HCC
ACHN

Hirtle Callaghan & Co’s Achillion Pharmaceuticals ACHN Stock Holding History

Hirtle Callaghan & Co’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-7,000
Closed -$86K – 408
2014
Q4 		$86K Hold
7,000
– – 0.02% 249
2014
Q3 		$70K Hold
7,000
– – 0.01% 274
2014
Q2 		$53K Sell
7,000
-15,000
-68% -$59.9K 0.01% 351
2014
Q1 		$72K Sell
22,000
-5,500
-20% -$19.2K 0.01% 311
2013
Q4 		$91K Buy
27,500
+16,500
+150% +$47.9K 0.01% 277
2013
Q3 		$33K Buy
+11,000
New +$75.4K 0.01% 386

Other funds holding ACHN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Hirtle Callaghan & Co's ACHN Position: Q1 2015 in Review

Hirtle Callaghan & Co sold out of Achillion Pharmaceuticals (ACHN) in Q1 2015, closing a stake of 7,000 shares — an estimated $86K sold.

Hirtle Callaghan & Co first reported a position in ACHN in Q3 2013 and held it in 6 quarters. The position peaked at $91K in Q4 2013. 173 funds tracked by Wall St. Rank hold ACHN as of Q1 2015.

  • Hirtle Callaghan & Co reported no remaining Achillion Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • Hirtle Callaghan & Co sold 7,000 Achillion Pharmaceuticals shares in Q1 2015, an estimated $86K.
  • Hirtle Callaghan & Co first reported a position in Achillion Pharmaceuticals in Q3 2013 and held it in 6 quarters.
  • Hirtle Callaghan & Co's Achillion Pharmaceuticals position peaked at $91K in Q4 2013.
  • 173 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2015.

Based on Hirtle Callaghan & Co's 13F filing for Q1 2015, filed 15 May 2015.